That's the one paused, soon resumed and the best part, hardly cost CHM any $$$$
(1) CHM 0201 Combination Clinical Trials
CHM 0201 + Vactosertib Phase 1B Clinical Trial at Case Western Reserve University
In January 2023, the first patient was treated in a Phase 1B clinical trial studying CHM 0201 in
combination with IL-2 and Vactosertib, an oral TGF-β receptor. The trial was designed to study 12
patients with colorectal cancer or Acute Myeloid Leukemia and is the first study to explore NK cells in
combination with Vactosertib. Although the trial was paused in early 2024 due to a lack of staff
resources at Case Western, the company expects the clinical trial to be resumed shortly and anticipates
completion of the clinical trial in 2024
Ann: Clinical milestones for 2024 & 2023 successes highlighted, page-3
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.951M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.2¢ | 1.0¢ | $38.54K | 3.639M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 2646760 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 729690 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| CHM (ASX) Chart |